Evidence map›Paper›PMID 28946792›Full record

ArticleTissue engineering. Part A2017

Gloria Gronowicz, Emily Jacobs, Tao Peng, Li Zhu, Marja Hurley, Liisa T Kuhn

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Bone Tissue Engineering in the Treatment of Bone Defects.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gloria Gronowicz1 Department of Surgery, University of Connecticut Health Center , Farmington, Connecticut.
Emily Jacobs2 Department of Biomedical Engineering, University of Connecticut Health Center , Farmington, Connecticut.
Tao Peng2 Department of Biomedical Engineering, University of Connecticut Health Center , Farmington, Connecticut.
Li Zhu2 Department of Biomedical Engineering, University of Connecticut Health Center , Farmington, Connecticut.
Marja Hurley3 Department of Medicine, University of Connecticut Health Center , Farmington, Connecticut.
Liisa T Kuhn2 Department of Biomedical Engineering, University of Connecticut Health Center , Farmington, Connecticut.
UConn Health · US

Funding

Modulated release of growth factors for stimulating progenitors in aging boneR01DE021103 · NIDCR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUHN, LIISA TIINA · 2012 to 2025
$4.4M
NIDCR NIH HHS R01 DE021103
6 · The paper itself

Abstract

A drug delivery coating for synthetic bone grafts has been developed to provide sequential delivery of multiple osteoinductive factors to better mimic aspects of the natural regenerative process. The coating is composed of a biomimetic calcium phosphate (bCaP) layer that is applied to a synthetic bone graft and then covered with a poly-l-Lysine/poly-l-Glutamic acid polyelectrolyte multilayer (PEM) film. Bone morphogenetic protein-2 (BMP-2) was applied before the coating process directly on the synthetic bone graft and then, bCaP-PEM was deposited followed by adsorption of fibroblast growth factor-2 (FGF-2) into the PEM layer. Cells access the FGF-2 immediately, while the bCaP-PEM temporally delays the cell access to BMP-2. In vitro studies with cells derived from mouse calvarial bones demonstrated that Sca-1 and CD-166 positive osteoblast progenitor cells proliferated in response to media dosing with FGF-2. Coated scaffolds with BMP-2 and FGF-2 were implanted in mouse calvarial bone defects and harvested at 1 and 3 weeks. After 1 week in vivo, proliferation of cells, including Sca-1+ progenitors, was observed with low dose FGF-2 and BMP-2 compared to BMP-2 alone, indicating that in vivo delivery of FGF-2 activated a similar population of cells as shown by in vitro testing. At 3 weeks, FGF-2 and BMP-2 delivery increased bone formation more than BMP-2 alone, particularly in the center of the defect, confirming that the proliferation of the Sca-1 positive osteoprogenitors by FGF-2 was associated with increased bone healing. Areas of bone mineralization were positive for double fluorochrome labeling of calcium and alkaline phosphatase staining of osteoblasts, along with increased TRAP+ osteoclasts, demonstrating active bone formation distinct from the bone-like collagen/hydroxyapatite scaffold. In conclusion, the addition of a bCaP layer to PEM delayed access to BMP-2 and allowed the FGF-2 stimulated progenitors to populate the scaffold before differentiating in response to BMP-2, leading to improved bone defect healing.

Indexed as

Biomimetic MaterialsBone Morphogenetic Protein 2Calcium PhosphatesCoated Materials, BiocompatibleFibroblast Growth Factor 2SkullAnimalsFemaleMiceMice, TransgenicNIH 3T3 CellsBmp2 protein, mouseBone Morphogenetic Protein 2calcium phosphateCalcium PhosphatesCoated Materials, BiocompatibleFibroblast Growth Factor 2bone morphogenetic protein-2bone tissue engineeringcalcium phosphatefibroblast growth factor-2polyelectrolyte multilayer

Identifiers

PMID28946792
PMCPMC5729881
OpenAlexW2757912736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.